Cidara Therapeutics Inc. (CDTX) has announced a reduction in its workforce by approximately 30% to concentrate on advancing the clinical development of CD388, the company's innovative DFC candidate targeting influenza A and B.The strategic initiatives are expected to substantially reduce capital needs and allow Cidara to focus on its planned Phase 2b and potential subsequent trials investigating CD388 as a single-dose, universal preventative for influenza A and B.The company continues business development discussions for its oncology drug-Fc conjugate (DFC) programs, including CBO421, a CD73 inhibitor, which recently received IND-clearance to commence a Phase 1 study..

Cidara Therapeutics Inc.（CDTX）宣布将其员工人数减少约30%，以专注于推进CD388的临床开发，CD388是该公司针对甲型和乙型流感的创新DFC候选药物。预计这些战略举措将大大减少资本需求，并使Cidara能够专注于其计划的2b期和潜在的后续试验，研究CD388作为甲型和乙型流感的单剂量通用预防剂。该公司继续就其肿瘤药物Fc偶联物（DFC）计划进行业务发展讨论，包括CD73抑制剂CBO421，该药最近获得IND批准，开始了一期研究。。

CDTX closed Thursday's regular trading at $11.35 down $0.27 or 2.32%. In the after-hours trading, the stock further dropped $0.49 or 4.35%. For comments and feedback contact: editorial@rttnews.comBusiness News

CDTX周四常规交易收于11.35美元，下跌0.27美元，跌幅2.32%。在盘后交易中，该股进一步下跌0.49美元，跌幅为4.35%。如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻

Biotech Stocks Facing FDA Decision In August 2024

2024年8月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In June 2024

2024年6月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局决定生物技术股